Labsystems also announced the availability of its new generation NeoMass AAAC
Labsystems Diagnostics, Helsinki, an enterprise of Trivitron Healthcare, headquartered in Chennai, entered into a joint association with Shimadzu Corporation, Japan, leader in analytical instruments, for clinical diagnostics in the area of Newborn Screening (NBS). NBS is a preventive paediatric screening service to assess the occurrence of genetic metabolic disorders.
Labsystems furthermore has announced the availability of its new generation NeoMass AAAC assay fully validated on Shimadzu mass spectrometry platforms. NeoMass AACC will enable investigators for the first time to detect the entire spectrum of Urea Cycle Metabolic Disorders (UCMD) in newborns.
- Advertisement -
Comments are closed.